🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,413 results for “ACE” Clear

  1. LCZ696 (sacubitril/valsartan)

    Novartis Pharmaceuticals

    Acute Myocardial Infarction

    phase 3 small molecule completed

    1 trial

  2. LETROZOLE, Arimidex® 1 mg Filmtabletten, Camizestrant, ABEMACICLIB, GOSERELIN, TRIPTORELIN, LEUPRORELIN ACETATE, Nolvadex® 20 mg Filmtabletten, EXEMESTANE

    AstraZeneca AB

    ER+/HER2- Early Breast Cancer

    phase 3 small molecule active

    1 trial

  3. LETROZOLE, DOCETAXEL, ANASTROZOLE, LEUPRORELIN ACETATE, LEUPRORELIN ACETATE, TAMOXIFEN, EPIRUBICIN, DOXORUBICIN, GOSERELIN, TRIPTORELIN, EXEMESTANE, PACLITAXEL, CYCLOPHOSPHAMIDE, GOSERELIN, TRIPTORELIN

    Ningbo Cancer Hospital

    Premenopausal patients with high-risk HR-positive/HER2-negative breast cancer (BC) defined by tumour size and axillary lymph node status. One of the following must apply: a. 1-3 lymph nodes involved AND any invasive tumour size. b. node negative (including micrometastases in at least 1 node [i.e. deposit >0.2-2mm diameter]) AND invasive tumour size ≥ 50mm.

    phase 3 small molecule active

    1 trial

  4. LETROZOLE, ELACESTRANT, ANASTROZOLE, EXEMESTANE, TAMOXIFEN, ELACESTRANT

    Stemline Therapeutics B.V.

    Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence

    phase 3 small molecule active

    1 trial

  5. LETROZOLE, PALBOCICLIB, Inavolisib placebo, LETROZOLE ACCORD HEALTHCARE 2,5 mg, comprimé pelliculé, IBRANCE 75 mg film-coated tablets, IBRANCE 125 mg film-coated tablets, Letrozol STADA® 2,5 mg Filmtabletten, INAVOLISIB, IBRANCE 100 mg film-coated tablets, INAVOLISIB, RIBOCICLIB, PALBOCICLIB, RIBOCICLIB, PALBOCICLIB

    Hoffmann-La Roche

    Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3CA)-Mutated, Hormone Receptor-Positive, human epidermal growth factor receptor 2- (HER2-) negative advanced breast cancer

    phase 3 small molecule active

    1 trial

  6. LEUPRORELIN ACETATE, BAY 1841788, NUBEQA 300 mg film-coated tablets, TRIPTORELIN, DEGARELIX, GOSERELIN

    Ningbo Cancer Hospital

    Castrate-resistant prostate cancer with oligometastases on functional imaging (PSMA or choline/fluciclovine-positron-emission tomography).

    phase 3 small molecule active

    1 trial

  7. LEUPRORELIN ACETATE, LEUPRORELIN ACETATE, ANASTROZOLE, GOSERELIN, LETROZOLE, GOSERELIN, EXEMESTANE, RIBOCICLIB

    Novartis Pharmaceuticals

    HR-positive HER-2- negative Breast Cancer

    phase 3 small molecule active

    1 trial

  8. LEVONOR,1 mg/ml, roztwór do infuzji

    COLLEGIUM PHARMACEUTICAL, INC

    hypotension in non-cardiac surgery

    phase 3 small molecule active

    1 trial

  9. LIBTAYO 350 mg concentrate for solution for infusion., matching Placebo with R2810

    Lacuna Pharma Pty Ltd

    Cutaneous Squamous Cell Carcinoma (CSCC)

    phase 3 small molecule active

    1 trial

  10. LIOTHYRONINE SODIUM , LEVOTHYROXINE SODIUM , Placebo tablets are white, round, biconvex tablets. The tablets contain no active pharmaceutical ingredient (API), but are manufactured following the manufacturing process of the liothyronine tablets presented in the IMPD for liotyronine 2, 2.5, 3.75, and 5 µg

    Disc Medicine

    Hypothyroidism Triiodothyronine Quality of Life Persistant complaints

    phase 3 small molecule active

    1 trial

  11. LMF237 50/250 mg

    Novartis Pharmaceuticals

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  12. LNP023

    Novartis Pharmaceuticals

    Primary IgA Nephropathy

    phase 3 small molecule active

    1 trial

  13. LOPERAMIDE , Ultra-Levura 250 mg cápsulas duras, Placebo to Saccharomyces boulardii

    Biocodex

    Non-constipated Irritable Bowel Syndrome (IBS)

    phase 3 small molecule active

    1 trial

  14. LORATADINE , FEXOFENADINE , Dupilumab, Matched placebo to test

    Sanofi-aventis Healthcare Pty Ltd

    Pruritus

    phase 3 small molecule active

    1 trial

  15. LOU064

    Novartis Pharmaceuticals

    Chronic Spontaneous Urticaria

    phase 3 small molecule active

    1 trial

  16. LOU064 (blinded)

    Novartis Pharmaceuticals

    Chronic Spontaneous Urticaria

    phase 3 small molecule completed

    1 trial

  17. LOU064, CLINDAMYCIN , Placebo to remibrutinib (lou064) 0 mg matching 00 mg film-coated tablet, LOU064, Placebo to remibrutinib (lou064) 0 mg matching 00 mg film-coated tablet, TRIAMCINOLONE , -

    Novartis Pharmaceuticals

    Hidradenitis Suppurativa (HS)

    phase 3 small molecule active

    1 trial

  18. LOU064, COLESTYRAMINE , TERIFLUNOMIDE, Placebo to teriflunomide 14 mg capsule, hard, Placebo to Remibrutinib (LOU064) 100 mg film-coated tablet, MEDICINAL CHARCOAL

    Novartis Pharmaceuticals

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  19. LOU064, Placebo to Remibrutinib (LOU064) XX mg film-coated tablet, -, -

    Novartis Pharmaceuticals

    Chronic Inducible Urticaria (CINDU)

    phase 3 small molecule active

    1 trial

  20. LOU064, Placebo to teriflunomide 14 mg capsule, hard, COLESTYRAMINE , Placebo to Remibrutinib (LOU064) 100 mg film-coated tablet, TERIFLUNOMIDE, MEDICINAL CHARCOAL

    Novartis Pharmaceuticals

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  21. LP352 (bexicaserin) Placebo Oral Solution, Bexicaserin

    Lacuna Pharma Pty Ltd

    Developmental and Epileptic Encephalopathies (DEE)

    phase 3 small molecule active

    1 trial

  22. LP352 (bexicaserin) Placebo Oral Solution, Bexicaserin

    Lacuna Pharma Pty Ltd

    Developmental and Epileptic Encephalopathies (DEEs)

    phase 3 small molecule active

    1 trial

  23. LPA1 antagonist, LPA1 antagonist, Placebo for BMS-986278

    Bristol-Myers Squibb Australia Pty Ltd

    Idiopathic pulmonary fibrosis

    phase 3 small molecule active

    1 trial

  24. LPA1 antagonist, Placebo for BMS-986278, LPA1 antagonist

    Bristol-Myers Squibb Australia Pty Ltd

    Progressive Pulmonary Fibrosis

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources